Occuity is delighted to announce its third consecutive attendance at 100% Optical, Europe's fastest-growing optical event. As we move...

As we approach the end of 2023, it's a fitting time to reflect on Occuity's progress throughout the year. Looking back, it's clear that...

We're very pleased to announce the successful completion of our Convertible Loan Note (CLN) investment round, which reached its target of...

Occuity is pleased to announce the filing of a new patent covering our novel approach to detecting and quantifying biomarkers in the eye....

We are pleased to announce a key milestone in Occuity's technology development strategy has been achieved. One of our recent patents,...

Occuity has recently unveiled an exciting partnership with Indo Optical, a multinational corporation boasting over seven decades of...

Many studies have been undertaken and books written, that demonstrate how diversity ultimately leads to more effective teams and better...

Over the past weekend, some of Occuity's senior leadership team headed to the vibrant city of San Francisco to participate in the eagerly...

Presentation of Internal Results on Investigating Effectiveness of SD1 Prototype to Identify Markers to Screen for Diabetes Occuity has...

The trailblazing technology and innovation behind the AX1 Axiometer™ have catapulted Occuity into the spotlight, earning us a coveted...

Occuity is pleased to announce our partnership with Argus Optik, a leading distributor of ophthalmic instruments and optical equipment...

Our vision, the most dominant of our senses, holds a pivotal role in every stage and aspect of our lives. Often, we fail to appreciate...

Occuity is pleased to announce our partnership with Designs For Vision, a leading distributor of ophthalmic equipment for over 50 years....

Occuity is pleased to announce our partnership with Laméris, a leading distributor of ophthalmic equipment for over 100 years. Under this...

Myopia Action Month It's Myopia Action Month, (September 2023) a new global initiative launched this year with a clear objective to...

Accompanied by Mark Jenkins, Occuity's Chief Operating Officer, I packed my bags and, bleary-eyed, headed off out the door. Ahead of us,...

The submission of the PM1 Pachymeter for FDA 510 (k) approval represents a critical milestone in launching the PM1 in the US market. A...

We are delighted to announce that Mark Jenkins, the Chief Operating Officer of Occuity, and Richard Kadri-Langford, the Head of Digital...

At Occuity, we're not just passionate about our technology and our products. We're equally passionate about our people, and the many...

Occuity is excited to announce the publication in the prestigious Journal of Ophthalmic & Physiological Optics (OPO) of the paper on the...